Page 45 - Bio Developments News Today

Pfizer and BioNTech have dosed the first participants in a Phase 2/3 study for their COVID-19 vaccine in pregnant women; and plan to trial the vaccine in children later this year.

Bristol Myers Squibb to leverage Molecular Template platform against multiple cancer targets Texas headquartered Molecular Templates (MTEM) has entered into a worldwide strategic research collaboration with Bristol Myers Squibb (BMS) to discover and develop multiple novel therapies designed for specific oncology targets. The oncology targets under this partnership and the duration of the alliance with BMS, however, have not been disclosed. The collaboration will se...

A new trial for the AstraZeneca/Oxford COVID-19 vaccine will investigate the efficacy of the vaccine in children aged six and over.

AbbVie and Caribou Biosciences have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.

Pic:getty/Yakobchuk Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a €300m ($363m) initiative announced on Monday. CDMO Recipharm will start production for Moderna at its Monts facility next month; while Delpharm will manufacture the Pfizer/BioNTech vaccine in Saint-Rémy-sur-Avre from April. In May, Fareva is set to follow suit for CureVa...

BioNTech announced this morning it has started the production of mRNA at its new facility in Marburg, Germany: which will become one of the largest mRNA manufacturing sites in Europe. The site will have an annual production capacity of up to 750 million doses of the Pfizer/BioNTech COVID-19 vaccine once fully operational. The first vaccines from the site are scheduled for distribution in April. mRNA production  Having received its first authorization in December, th...

Johns Hopkins Medicine researchers have studied the reaction of nearly 200 solid organ transplant recipients to their first COVID-19 vaccine shot. The findings, they say, suggest that the Moderna and Pfizer/BioNTech mRNA vaccines can be safely given to this immunocompromised population.

In the pipeline: What the next wave of COVID-19 vaccines could look like We take a look at some of the COVID-19 vaccine candidates moving through Phase 1 and 2 clinical trials - and how they could offer a point of difference to authorized vaccines. While vaccines from big names such as Pfizer/BioNTech, Moderna and AstraZeneca are rolling out across the world, there are currently 64 vaccines in clinical development, according to the latest figures from the World Heal...

Loxo Oncology at Lilly, an R&D division of Eli Lilly and Co, and Merus, a Dutch clinical-stage oncology company, today announced a partnership to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.

Previously Rexgenero Ltd, a UK-based company developing cell therapies to treat serious diseases such as cancer and CLTI, the launch of Ixaka Ltd follows the integration of its nanoparticle gene therapy business in France and a shareholder restructuring. The company reported that additional financing from existing shareholders, to the tune of over £40m (US$54.1m), will accelerate its proprietary multi-cell and targeted nanoparticle technologies. Asked why there w...